- Recruiting
NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
Updated: Jun 13, 2022
Multiple Myeloma Research Consortium
phase 2 study
Dara-KRd
NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.
Sponsor:
University of Chicago
Collaborators:
Janssen Scientific Affairs, LLC
Amgen
Multiple Myeloma Research Consortium
ClinicalTrials.gov Identifier: NCT03500445
Official Title: Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
First Posted: April 18, 2018
Click here for details on ClinicalTrials.gov
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Lenalidomide: National Cancer Institute
Lenalidomide: MedlinePlus Drug Information
Carfilzomib : National Cancer Institute
Carfilzomib : MedlinePlus Drug Information
Daratumumab : National Cancer Institute
Daratumumab : MedlinePlus Drug Information
Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
2759 A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Program: Oral and Poster Abstracts
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II
Hematology Disease Topics & Pathways:
Clinical Trials, Clinical Research, Plasma Cell Disorders, Clinically Relevant, Diseases, Lymphoid Malignancies
Sunday, December 12, 2021, 6:00 PM-8:00 PM
Conclusions: The combination of Dara-KRd as extended frontline therapy for NDMM without employing ASCT can induce high rates of MRD-negativity within 8 cycles, exceeding the historical sCR rate of KRd without Dara. Importantly, the rate and depth of MRD-negativity improve beyond cycle 8, suggesting that extended Dara-KRd without ASCT may generate rates of sCR and MRD-negativity comparable to KRd with ASCT. Yearly longitudinal determinations of MRD after completion of 24 cycles of Dara-KRD protocol treatment will generate information on the durability of MRD and the role of ASCT compared to shorter treatments with Dara-KRd, with and without ASCT.
Location
United States, Illinois